{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 10,
  "pageCount": 30,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": "The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/10",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.05,
        "x": 0.47,
        "y": 0.78
      },
      "kind": "callout",
      "text": "VS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74c69d28-85b2-43a9-a6f1-b6be8665483d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.53,
        "y": 0.72
      },
      "kind": "list",
      "text": "BAER-101 is a selective agonist at the α2 and α3 subunits. The goal of BAER-101 is to provide anticonvulsant and anxiolytic activity by minimizing adverse events and risk of tolerance and abuse",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81e9b296-a882-4622-8a3a-c64c5a4b80f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.45,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Benzodiazepines (BZDs) are non-selective agonists of the alpha subunits α1, α2, α3 and α5. BZDs have an extensive adverse event profile that can limit the dose and its effectiveness: somnolence, sedation, cognitive impairment, overuse, misuse and addiction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c93f68b7-ad3c-4b50-b8f9-b67ccf9a9c4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "table",
      "text": "Table comparing therapeutic and negative effects across alpha 1, 2, 3, and 5 GABA-A subtypes.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "008dcd40-bf31-4c5c-ae24-98bc41c12794",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "BAER-101 may have a more tolerable side effect profile compared to nonselective benzodiazepines due to greater GABA subtype selectively",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dc47687-2fc1-4909-a0b8-cd608569dc2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "title",
      "text": "Predicted effect of targeting GABAA subtypes",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93d63ca8-1638-428b-a891-c62d7cff8118",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "7fdb0838-3297-4cb0-85ab-9714d781fcf4",
      "evidence": "Comparison of BAER-101 vs Benzodiazepines",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 8,
      "beatId": "618a2f9e-df9a-49da-a0ea-04fb4bfa7948",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}